Supplementary Table 1. Baseline characteristic of study participants

Characteristic	Mild COVID-19 (n = 12)	Severe COVID-19 (n = 41)	ChAdOx1 (n = 37)	BNT161b2 (n = 36)	*p* value
Age, yr	41 (33–51)	71 (61–77)	40 (33-46)	32 (26–36)	< 0.001
Age group					< 0.001
20s	2 (16.7)	0	4 (10.8)	16 (44.4)	
30s	3 (25.0)	0	13 (35.1)	15 (41.7)	
40s	3 (25.0)	0	15 (40.5)	4 (11.1)	
50s	3 (25.0)	9 (22.0)	4 (10.8)	1 (2.8)	
60s and above	1 (8.3)	32 (78.0)	1 (2.7)	0	
Sex					0.075
Female	8 (66.7)	15 (36.6)	22 (59.5)	22 (61.1)	
Male	4 (33.3)	26 (63.4)	15 (40.5)	14 (38.9)	
Underlying diseases					
Hypertension	3 (25.0)	25 (61.0)	3 (8.1)	0	< 0.001
Diabetes mellitus	0	10 (24.4)	1 (2.7)	0	< 0.001
Cardiovascular disease	0	5 (12.2)	0 (0.0)	0	0.013
Chronic lung disease	0	6 (14.6)	0 (0.0)	0	0.005
Chronic kidney disease	0	4 (9.8)	1 (2.7)	0	0.125
Chronic liver disease	1 (8.3)	2 (4.9)	0	0	0.194
Solid cancer	1 (8.3)	4 (9.8)	0	0	0.065
Hematologic malignancy	1 (8.3)	3 (7.3)	0	0	0.126
Smoking	0	2 (4.9)	0	0	0.239
Pregnancy	1 (8.3)	0	0	0	0.023
Treatment					
Steroid	0	25 (61)	NA	NA	< 0.001
Remdesivir	0	30 (73.2)	NA	NA	< 0.001
Convalescent plasma therapy[a]	0	7 (17.1)	NA	NA	0.329
Immunomodulator[b]	0	7 (17.1)	NA	NA	0.329
Clinical course			NA	NA	0.576
Discharge as protocol[c]	12 (100)	36 (87.8)	NA	NA	
Death	0	5 (12.2)	NA	NA	

Values are presented as median (interquartile range) or number (%).
COVID-19, coronavirus disease 2019; NA, not applicable.
[a]Including GC5131 of GC pharma and Rekirona (CT-P59, regdanvimab) of Celltrion.
[b]Including barcitinib and tocilizumab.
[c]10 days pass from date of diagnosis without clinical symptoms or two consecutive negative results of PCR test at 24-hour interval without clinical symptoms.

https://doi.org/10.3904/kjim.2021.409